IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Bender et al.

Serial No. :

Art Unit:

Filed

: December 13, 2001

Examiner:

For

: Cloning and Expression of a Novel 5-HT4 Receptor

I hereby certify that this correspondence is being deposited with the United States Postal Service as express mail in an envelope addressed to: Commissioner For Patents, Washington, D.C. 20231 on

December 13, 2001

Myra H. McCormack (Name of applicant, assignee, or Registered Representative)

December 13, 2001

(Date of Signature)

Commissioner for Patents Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §\$1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this

information may n e enabling for the teach purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under \$1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in \$1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under \$1.114, no additional fee is required.

in ac	ccordance with \$1.129(a), this information	
Disclosure Stat	ement is being filed in connection with \square the	
first or □seco	and After Final Submission, therefore:	
	Statement in Accordance with §1.97(e) (attached);
	or	
	Please charge Deposit Account No. 10-0750/	/
	the fee of $$180.00$ as set forth in $$1.17(p)$.	

In accordance with §1.97(c), this Information


Disclosure Statement is being filed after the period set forth

in §1.97(b) above but before the mailing date of either a Final

Action under §1.113 or a Notice of Allowance under §1.311, or an

action that otherwise closes prosecution and that it is

accompanied by one of:



- 3 -

The relation of those listed references which are not in the English language is as follows:
Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.
Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.
Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/JAB-1517/MHM. This form is submitted in triplicate. Respectfully submitted,
Myra H. McCormack Reg. No. 36602 Attorney for Applicants

Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 (732) 524-6932 DATED: December 13, 2001

PTO/SB/08A (08-00) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DePARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 2

a condition of information unless it displays a	I VANO CIVID COLLUCI HUITIDAL.
Application Number	
Filing Date	December 12, 2001
First Named Inventor	Bender, et al
Group Art Unit	
Examiner Name	
Attorney Docket Number	JAB-1517

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite	U.S. Patent Document				
		Kind Code ²		Name of Patentee or Applicant	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant passages
		Number	(if known)	of Cited Document	mm-dd-yyyy	or relevant figures appear
				20 20 20 20 20 20 20 20 20 20 20 20 20 2		
				· · · · · · · · · · · · · · · · · · ·		

FOREIGN PATENT DOCUMENTS Foreign Patent Document **Date of Publication** Pages, Columns, Lines, of Cited Document where relevant Name of Patentee or Examiner Cite passages or relevant T⁵ mm-dd-yyyy Applicant of Cited Document Initials Office³ Number⁴ KindCode⁵ figures appear No.1 WO 00/77199 Α Janssen Pharmaceuticals N V 12/21/2000 wo 94/14957 Synaptic Pharmaceutical Corporation Α 7/7/1994

Examiner	Date
Signature	Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office. Washington. DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 2

a conscion of unormation unless it displays a	TORO OND CONDUCTIONIDGI.
Application Number	0/018257
Filing Date	December 12, 2001
First Named Inventor	B nder et al.
Group Art Unit	
Examiner Name	
Attorney Docket Number	JAB-1517

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials*	Cite No.1	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
	1	Eckard Bender, Armelle Pindon, Irma van Oers, Yu-Bin Zhang, Walter Gommeren, Peter Verhasselt, Mirek Jurzak, Josee Leysen, and Walter Luyten, "Stucture of the Human Serotonin 5-HT(4) Receptor Gene and Cloning of a Novel 5-HT(4) Splice Variant" Journal of Neurochemistry, 2000, XP-000953119, PP. 478-83	
	2	Olivier Blondel, Monique Gastineau, Yamina Dahmoune, Michel Langlois, and Rodolphe Fischmeister, "Cloning, Expression and Pharmacology of Four Human 5-hydroxytryptamine(4) Receptor Isoforms Produced by Alternative Splicing in the Carboxyl Terminus, Journal of Neurochemistry, 1998, XP-000953121, PP. 2252-61.	
 			
.			
	İ		<u> </u>
ļ			
			
			
			<u> </u>
	I		

Examiner	Date
Signature	Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.